Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: A preliminary assessment - Clinical article

Journal of Neurosurgery

Volumn 119, Issue 6, 2013, Pages 1611-1619

  Simard, J Marc ^a   Aldrich, E Francois ^a   Schreibman, David ^a   James, Robert F ^a,b   Polifka, Adam ^a   Beaty, Narlin ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cerebral vasospasm; Heparin; Inflammation; Subarachnoid hemorrhage; Vascular disorders

Indexed keywords

HEPARIN; NIMODIPINE; VERAPAMIL;

ADULT; ANEURYSM CLIP; ANEURYSM RUPTURE; APHASIA; ARTICLE; BRAIN INFARCTION; CARDIOPULMONARY INSUFFICIENCY; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; FEMALE; HEMIPARESIS; HEMIPLEGIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTENSION; LIMB WEAKNESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NEUROLOGIC DISEASE; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SACCULAR ANEURYSM; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; THROMBOSIS PREVENTION;

EID: 84889260703     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2013.8.JNS1337     Document Type: Article

References (77)

1. Amiconi G, Zolla L, Vecchini P, Brunori M, Antonini E: The effect of macromolecular polyanions on the functional properties of human hemoglobin. Eur J Biochem 76:339-343, 1977
2. Attanasio M, Gori AM, Giusti B, Pepe G, Comeglio P, Brunelli T, et al: Cytokine gene expression in human LPS- and IFN-gamma-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost 79:959-962, 1998
3. Barry WH, Kennedy TP: Heparins with reduced anti-coagulant activity reduce myocardial reperfusion injury. Recent Patents Cardiovasc Drug Discov 6:148-157, 2011
4. Bederson JB, Connolly ES Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, et al: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 40:994-1025, 2009
5. Boneu B, Dol F, Caranobe C, Sie P, Houin G: Pharmacokinetics of heparin and related polysaccharides. Ann N Y Acad Sci 556:282-291, 1989
6. Casu B: Structure of heparin and heparin fragments. Ann N Y Acad Sci 556:1-17, 1989
7. Chansel D, Ciroldi M, Vandermeersch S, Jackson LF, Gomez AM, Henrion D, et al: Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J 20:1936-1938, 2006
8. Chimowitz MI, Pessin MS: Is there a role for heparin in the management of complications of subarachnoid hemorrhage? Stroke 18:1169-1172, 1987
9. Conway JE, Tamargo RJ: Cocaine use is an independent risk factor for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke 32:2338-2343, 2001
10. Coombe DR: Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol 86:598-607, 2008
11. Crowley RW, Medel R, Kassell NF, Dumont AS: New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today 13:254-260, 2008
12. Daneschvar HL, Daw H: Heparin-induced thrombocytopenia (an overview). Int J Clin Pract 61:130-137, 2007
13. Dawes J, Prowse CV, Pepper DS: Absorption of heparin, LMW heparin and SP54 after subcutaneous injection, assessed by competitive binding assay. Thromb Res 44:683-693, 1986
14. Deshaies EM, Boulos AS, Popp AJ: Peri-operative medical management of cerebral vasospasm. Neurol Res 31:644-650, 2009
15. Duschek N, Vafaie M, Skrinjar E, Hirsch K, Waldhör T, Hübl W, et al: Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial. J Thromb Haemost 9:2159-2167, 2011
16. Edelman ER, Karnovsky MJ: Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 89:770-776, 1994
17. Elsayed E, Becker RC: The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 15:11-18, 2003
18. Engelberg H: Actions of heparin that may affect the malignant process. Cancer 85:257-272, 1999
19. Etminan N, Vergouwen MD, Macdonald RL: Angiographic vasospasm versus cerebral infarction as outcome measures after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 115:33-40, 2013
20. Feng Y, Green B, Duffull SB, Kane-Gill SL, Bobek MB, Bies RR: Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Br J Clin Pharmacol 62:165-176, 2006
21. Fergusen S, Macdonald RL: Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 60:658-667, 2007
22. Fisher CM, Kistler JP, Davis JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6:1-9, 1980
23. Gandhi NS, Mancera RL: The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 72:455-482, 2008
24. Hansen-Schwartz J: Cerebral vasospasm: a consideration of the various cellular mechanisms involved in the pathophysiology. Neurocrit Care 1:235-246, 2004
25. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N: Membrane-anchored growth factors, the epidermal growth factor family: beyond receptor ligands. Cancer Sci 99:214-220, 2008
26. Higashiyama S, Nanba D: ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 1751:110-117, 2005
27. Hirsh J, Anand SS, Halperin JL, Fuster V: Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 21:1094-1096, 2001
28. Hochart H, Jenkins PV, Preston RJ, Smith OP, White B, O'Donnell J: Concentration-dependent roles for heparin in modifying lipopolysaccharide- induced activation of mononuclear cells in whole blood. Thromb Haemost 99:570-575, 2008
29. Hochart H, Jenkins PV, Smith OP, White B: Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 133:62-67, 2006
30. Hoh BL, Curry WT Jr, Carter BS, Ogilvy CS: Computed tomographic demonstrated infarcts after surgical and endovascular treatment of aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien) 146:1177-1183, 2004
31. Iba T, Takayama T: Enoxaparin attenuates endothelial damage with less bleeding compared with unfractionated heparin in endotoxemic rats. Shock 32:530-534, 2009
32. Ibrahim GM, Weidauer S, Vatter H, Raabe A, Macdonald RL: Attributing hypodensities on CT to angiographic vasospasm is not sensitive and unreliable. Stroke 43:109-112, 2012
33. Joseph M, Ziadi S, Nates J, Dannenbaum M, Malkoff M: Increases in cardiac output can reverse flow deficits from vasospasm independent of blood pressure: a study using xenon computed tomographic measurement of cerebral blood flow. Neurosurgery 53:1044-1052, 2003
34. Junqueira DR, Perini E, Penholati RR, Carvalho MG: Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 9:CD007557, 2012
35. Juvela S, Siironen J, Varis J, Poussa K, Porras M: Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. J Neurosurg 102:194-201, 2005
36. Kalmes A, Daum G, Clowes AW: EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci 947:42-55, 2001
37. Kandrotas RJ: Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 22:359-374, 1992
38. Kane-Gill SL, Feng Y, Bobek MB, Bies RR, Pruchnicki MC, Dasta JF: Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety. J Clin Pharm Ther 30:207-213, 2005
39. Kapp JP, Neill WR, Neill CL, Hodges LR, Smith RR: The three phases of vasospasm. Surg Neurol 18:40-45, 1982
40. Kapp JP, Neill WR, Salter JE, Barnes TY: Systemic heparin in the early management of ruptured intracranial aneurysms: review of 104 consecutive cases and comparison with concurrent controls. Neurosurgery 20:564-570, 1987
41. Keuskamp J, Murali R, Chao KH: High-dose intraarterial verapamil in the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg 108:458-463, 2008
42. Kranc KR, Pyne GJ, Tao L, Claridge TD, Harris DA, Cadoux-Hudson TA, et al: Oxidative degradation of bilirubin produces vasoactive compounds. Eur J Biochem 267:7094-7101, 2000
43. Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, et al: Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86:1370-1375, 1992
44. Kuwahara-Watanabe K, Hidai C, Ikeda H, Aoka Y, Ichikawa K, Iguchi N, et al: Heparin regulates transcription of endothelin-1 gene in endothelial cells. J Vasc Res 42:183-189, 2005
45. Lever R, Smailbegovic A, Page CP: Locally available heparin modulates inflammatory cell recruitment in a manner independent of anticoagulant activity. Eur J Pharmacol 630:137-144, 2010
46. Li X, Zheng Z, Li X, Ma X: Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 60:114-121, 2012
47. Lindahl U, Lidholt K, Spillmann D, Kjellén L: More to "heparin" than anticoagulation. Thromb Res 75:1-32, 1994
48. Macdonald RL, Pluta RM, Zhang JH: Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3:256-263, 2007
49. Meyer R, Deem S, Yanez ND, Souter M, Lam A, Treggiari MM: Current practices of triple-H prophylaxis and therapy in patients with subarachnoid hemorrhage. Neurocrit Care 14: 24-36, 2011
50. Morrison AM, Wang P, Chaudry IH: A novel nonanticoagulant heparin prevents vascular endothelial cell dysfunction during hyperdynamic sepsis. Shock 6:46-51, 1996
51. Mulloy B: The specificity of interactions between proteins and sulfated polysaccharides. An Acad Bras Cienc 77:651-664, 2005
52. Otten ML, Mocco J, Connolly ES Jr, Solomon RA: A review of medical treatments of cerebral vasospasm. Neurol Res 30:444-449, 2008
53. Provencio JJ, Vora N: Subarachnoid hemorrhage and inflammation: bench to bedside and back. Semin Neurol 25:435-444, 2005
54. Pyne-Geithman GJ, Caudell DN, Prakash P, Clark JF: Glutathione peroxidase and subarachnoid hemorrhage: implications for the role of oxidative stress in cerebral vasospasm. Neurol Res 31:195-199, 2009
55. Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, et al: Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol 299:C97-C110, 2010
56. Ray WZ, Strom RG, Blackburn SL, Ashley WW, Sicard GA, Rich KM: Incidence of deep venous thrombosis after subarachnoid hemorrhage. Clinical article. J Neurosurg 110:1010-1014, 2009
57. Rider CC: Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem Soc Trans 34:458-460, 2006
58. Rothoerl RD, Ringel F: Molecular mechanisms of cerebral vasospasm following aneurysmal SAH. Neurol Res 29:636-642, 2007
59. Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, et al: No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebocontrolled clinical trial. J Neurosurg 99:953-959, 2003
60. Simard JM, Schreibman D, Aldrich EF, Stallmeyer B, Le B, James RF, et al: Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage. Neurocrit Care 13:439-449, 2010
61. Simard JM, Tosun C, Ivanova S, Kurland DB, Hong C, Radecki L, et al: Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage. Transl Stroke Res 3 (Suppl 1):155-165, 2012
62. Stein SC, Levine JM, Nagpal S, LeRoux PD: Vasospasm as the sole cause of cerebral ischemia: how strong is the evidence? Neurosurg Focus 21(3):E2, 2006
63. Suarez JI, Tarr RW, Selman WR: Aneurysmal subarachnoid hemorrhage. N Engl J Med 354:387-396, 2006
64. Triantaphyllopoulos DC, Triantaphyllopoulos E: Solubility of fibrin clots in solutions of heparin. Nature 204:1096-1098, 1964
65. Tseng MY: Summary of evidence on immediate statins therapy following aneurysmal subarachnoid hemorrhage. Neurocrit Care 15:298-301, 2011
66. Tyrell DJ, Kilfeather S, Page CP: Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 16:198-204, 1995
67. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP: Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46:151-208, 1999
68. US Food and Drug Administration: Heparin: change in reference standard. FDA.gov. (http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm184687.htm) [Accessed August 13, 2013]
69. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL: Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab 31:1545-1553, 2011
70. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:1761-1770, 2008
71. Wang DZ, Futrell N, Taylon C, Millikan C: Anticoagulation for prevention of cerebral infarcts following subarachnoid hemorrhage. Surg Neurol 44:270-274, 1995
72. Weir BK, Kongable GL, Kassell NF, Schultz JR, Truskowski LL, Sigrest A: Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: a report of the Cooperative Aneurysm Study. J Neurosurg 89:405-411, 1998
73. Weyer GW, Nolan CP, Macdonald RL: Evidence-based cerebral vasospasm management. Neurosurg Focus 21(3):E8, 2006
74. Wurm G, Tomancok B, Nussbaumer K, Adelwöhrer C, Holl K: Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg 106:97-103, 2004
75. Yokokawa K, Mandal AK, Kohno M, Horio T, Murakawa K, Yasunari K, et al: Heparin suppresses endothelin-1 action and production in spontaneously hypertensive rats. Am J Physiol 263:R1035-R1041, 1992
76. Young E: The anti-inflammatory effects of heparin and related compounds. Thromb Res 122:743-752, 2008
77. Zhang ZD, Macdonald RL: Contribution of the remodeling response to cerebral vasospasm. Neurol Res 28:713-720, 2006